Canagliflozin (CANA) Demonstrates Durable Glycemic Improvements Over 104 Weeks versus Glimepiride (GLIM) in Subjects with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) - Cefalu, W T; Leiter, L A; Yoon, K H (Diabetes, 2013)
et al.